Session 6: Treatment tailoring according to pathology and biology

Chairs: Hervé Bonnefoi (France), Meredith Regan (USA)

• Integrating multigene signatures in the management of primary breast cancer: Who needs it? (Stefan Aebi, Switzerland)
• Treatment selection for patients with low and equivocal ER status (Hope Rugo, USA)
• Treatment selection for patients with equivocal HER2 status and in luminal versus HER2 enriched disease (Giuseppe Viale, Italy)
• Treatment selection for patients with BRCA mutation (Judy Garber, USA)

BCC2019 PARTICIPANT: PASSWORD in BCC e-mail from March 23.